Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial Julio Rosenstock, MD; Steven E. Kahn, MB, ChB; Odd Erik Johansen, MD, PhD; et al. Editorial: Sulfonylureas and Cardiovascular Safety: The Final Verdict?; Deborah J. Wexler, MD, MSc Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function Christianne L. Roumie, MD, MPH; Jonathan Chipman, PhD; Jea Young Min, PharmD, MPH, PhD; et al. Editorial: Sulfonylureas and Cardiovascular Safety: The Final Verdict?; Deborah J. Wexler, MD, MSc EDITORIAL Sulfonylureas and Cardiovascular Safety: The Final Verdict? Deborah J. Wexler, MD, MSc

TRENDING NOW ON JAMA NETWORK OPEN Emergency Clinicians’ Assessment of Mortality Risk and Actual 1-Month Mortality Among Older Adults Contextual Factors Associated With County-Level Suicide Rates in the United States Concordance Between Electronic Clinical Documentation and Physicians’ Observed Behavior Working Memory Development and Motor Vehicle Crashes in Young Drivers Age and Birth Cohort–Adjusted Rates of Suicide Mortality Among US Youths From 1999 to 2017

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis